T lymphocytes redirected against the chondroitin sulfate proteoglycan-4 control the growth of multiple solid tumors both in vitro and in vivo

Claudia Geldres\textsuperscript{1,5}, Barbara Savoldo\textsuperscript{1,2}, Valentina Hoyos\textsuperscript{1}, Ignazio Caruana\textsuperscript{1}, Ming Zhang\textsuperscript{1}, Eric Yvon\textsuperscript{1}, Michele Del Vecchio\textsuperscript{1}, Chad J Creighton\textsuperscript{9}, Michael Ittmann\textsuperscript{3,5,8} Soldano Ferrone\textsuperscript{10} and Gianpietro Dotti\textsuperscript{1,3,4,5,6}\textsuperscript{*}

\textsuperscript{1}Center for Cell and Gene Therapy and Departments of \textsuperscript{2}Pediatrics, \textsuperscript{3}Pathology and Immunology, and \textsuperscript{4}Medicine, \textsuperscript{5}Interdepartmental Program in Translational Biology and Molecular Medicine, Baylor College of Medicine, Houston, Texas, \textsuperscript{6}Houston Methodist Hospital and Texas Children’s Hospital, Houston, TX. \textsuperscript{7}Department of Surgery, \textsuperscript{8}Michael E. DeBakey Department of Veterans Affairs Medical Center, \textsuperscript{9}Dan L. Duncan Cancer Center Division of Biostatistics, Baylor College of Medicine, Houston, Texas, \textsuperscript{10}Massachusetts General Hospital, Harvard Medical School, Boston, MA

*Address Correspondence to:

\textbf{Gianpietro Dotti}

Center for Cell and Gene Therapy
Baylor College of Medicine
6621 Fannin St. MC 3-3320
Houston, TX 77030
Phone: (832) 824-6891
Fax: (832) 825-4732
E-mail: gdotti@bcm.edu

\textbf{Disclosure of Potential Conflicts of Interest}: Center for Cell and Gene Therapy has a collaborative research agreement with Celgene and Bluebird bio.

\textbf{Running title}: CSPG4-Specific CAR in Solid Tumors.

\textbf{Funding}: This work was supported in part by RP110553 CPRIT Cellular Therapy of Cancer, P30 CA125123 NCI supporting the Human Tissue Acquisition and Pathology and Statistics and Bioinformatics Core Resources of the Dan L. Duncan Cancer and NIH CA 138188.

\textbf{Acknowledgements}: The authors would like to thank Dr Malcolm Brenner for the critical revision of the manuscript.
ABSTRACT

Purpose: Because of its high expression on various types of tumors and its restricted distribution in normal tissues, chondroitin sulfate proteoglycan-4 (CSPG4) represents an attractive target for the antibody-based therapy of several solid tumors. We tested whether T cells transduced with a CSPG4-specific chimeric antigen receptor (CAR) inhibited the growth of CSPG4-expressing tumor cells both in vitro and in vivo.

Experimental Design: We first independently validated by immunohistochemistry (IHC) the expression of CSPG4 in an extensive panel of tumor arrays and normal tissues as well as queried public gene expression profiling datasets of human tumors. We constructed a second generation CSPG4-specific CAR also encoding the CD28 costimulatory endodomain (CAR.CSPG4). We then evaluated human T lymphocytes expressing this CAR for their ex vivo and in vivo anti-tumor activity against a broad panel of solid tumors.

Results: IHC showed that CSPG4 is highly expressed in melanoma, breast cancer, head and neck squamous cell carcinoma (HNSCC) and mesothelioma. In addition, in silico analysis of microarray expression data identified other important potential tumors expressing this target, including glioblastoma, clear cell renal carcinoma and sarcomas. T lymphocytes genetically modified with a CSPG4-CAR controlled tumor growth in vitro and in vivo in NSG mice engrafted with human melanoma, HNSCC and breast carcinoma cell lines.

Conclusions: CAR.CSPG4-redirected T cells should provide an effective treatment modality for a variety of solid tumors.
TRANSLATIONAL RELEVANCE

Adoptive transfer of CAR-redirected T lymphocytes represents a promising therapy for patients with lymphoid malignancies. Here we extend the applicability of this strategy to a broad array of solid tumors by targeting the CSPG4 antigen; this antigen is over-expressed by numerous tumor types while having negligible expression in normal tissues. Our study provides preclinical evidence that CSPG4-redirected T cells can control the growth of human melanoma, HNSCC and breast cancer both ex vivo and in vivo in xenograft models.
Introduction

Chondroitin sulfate proteoglycan-4 (CSPG4), also known as high molecular weight-melanoma associated antigen (HMW) and melanoma-associated chondroitin sulfate proteoglycan (MCSP), is a well characterized cell surface proteoglycan first identified on human melanoma cells (1). Subsequent studies showed it to be highly expressed on other solid tumors such as mesothelioma (2) and triple negative breast carcinoma (3) all of which often show an aggressive clinical course. In contrast, CSPG4 has a restricted distribution in normal tissues (4). CSPG4 participates in tumor migration, invasion, angiogenesis, and metastasis (5). It interacts with α4β1 integrins to directly modulate cell adhesion, motility and metastasis as demonstrated by its ectopic expression in tumor cells (6). Given its restricted expression in normal tissues, high expression on various types of solid tumors and its role in the biology of tumor cells, CSPG4 is an attractive target for immunotherapy.

CSPG4 has been targeted with monoclonal antibodies (mAbs) in models of melanoma, mesothelioma, and breast carcinoma, resulting in the inhibition of tumor growth and survival in addition to thwarting the metastatic capability of tumor cells (7). Recent advances in potentiating the antitumor effects of a specific mAb rely on coupling its antigen-binding specificity with the effector function and long-term persistence of T lymphocytes to generate specific chimeric antigen receptors (CARs) (8-10). These molecules are obtained by fusing the extracellular antigen-binding domain of the mAb with the intracellular signaling domains derived from the CD3-ζ chain of the T-cell receptor, in tandem to costimulatory endodomains to support survival and proliferative signals (11-13). Since CAR-modified T cells function independently of a patient’s MHC and can readily be generated for clinical use (14-16), the value of targeting CSPG4 with a CAR based-approach is appealing.
We first validated the expression of CSPG4 in an extensive panel of tumor arrays and normal tissues as well as queried public gene expression profiling datasets of human tumors and confirmed its broad expression. We then generated a CSPG4-specific CAR (CAR.CSPG4) and showed that when expressed by T cells, not only was melanoma effectively targeted \textit{in vitro}, as previously demonstrated (17), but antitumor activity was observed \textit{in vitro} and \textit{in vivo} against many solid tumors including breast carcinoma, HNSCC and mesothelioma. Redirecting T cells to CSPG4 using CARs may thus represent a robust platform to target multiple solid tumors.
Materials and Methods

Cell lines. The previously described SENMA, CLB and P1143 tumor cell lines were generated in our laboratory from melanoma biopsies (18). MDA-MB-231 was originally obtained from American Type Culture Collection (ATCC) and authenticated by the analysis of short tandem repeat sequences performed at MD Anderson Cancer Center, Texas, USA. UACC-812, PCI-30 and PHI cell lines were provided by Dr Ferrone and these cells, when maintained in culture for several passages, retained the same phenotypic expression of CSPG4 as the early cell passages. Previously described melanoma cell lines PLAODE, NE-18732, NE-18588, NE-8959, NE-4405 and NE-371952 were only used to confirm the expression of CSPG4 in a broad array of melanoma cell lines (18). All these cells, including SENMA, CLB, and P1143, when maintained in culture for several passages, retained the same phenotypic expression of CSPG4 as the early cell passages. SENMA, CLB, UACC-812, MDA-MB-231, and PCI-30 cell lines were cultured in DMEM (Invitrogen Grand Island, NY) or RPMI 1640 (P1143, UACC-812, and PHI) (Cambrex, East Rutherford, NJ) medium supplemented with 10% heat inactivated fetal calf serum (FCS) (HyClone, Thermo Fisher Scientific Inc., Wyman, MA), 200 IU/mL penicillin, 200 mg/mL streptomycin (Invitrogen), and 2 mmol/L GlutaMAX (Invitrogen) at 37°C in a 5% CO₂ atmosphere. Tumor cell lines were transduced with a gamma retroviral vector encoding eGFP to obtain GFP⁺ tumor cells (>98% GFP⁺). Primary epithelial cells from normal small airway, kidney and prostate were purchased from ATCC and kept in culture according to ATCC recommendation.

Tissue microarrays and Immunohistochemistry (IHC). Antigen retrieval was performed by placing the samples in 1X Dako Citrate Buffer followed by incubation at 90°C in a pressure cooker for 45 minutes. After blocking with normal goat serum diluted in Tris-Buffered Saline, samples were incubated with the CSPG4 mAb (Abcam, Anti-NG2 antibody [LHM 2], ref#: ab104535) (1:300 dilution) either overnight at 4°C or at room temperature for 1 hour. Detection
of CSPG4 was then assessed using the VECTASTAIN® ABC kit (Vector Laboratories, Inc. ref# PK-4001) following the manufacturer's protocol. Tissue arrays were obtained from Cybrdi Inc (Rockville, MD) for breast cancer (CC08-10-001) and HNSCC (CC34-01-001), while melanoma (ME2082b), neuroblastoma (MC602), mesothelioma (T392), and normal tissue (FDA 808b) arrays were obtained from US Biomax, Inc. (Rockville, MD). Each array contained a range of 4 to 192 cores of tumor or 5 to 18 cores of normal tissue samples in duplicate, triplicate or quadruplicate in the case of mesothelioma. Expression of CSPG4 in tumor cells was scored in blind fashion by the pathologist Dr Michael Ittmann based on both intensity (0-3+) and extent of staining (1-3+). A multiplicative staining score was calculated by multiplying the intensity and extent scores to yield scores on a 10 point scale from 0-9 (19). In microarrays with multiple cores per patient, the individual scores were averaged to obtain a final score. In some cores, tumor was not identified due to artifacts. In the vast majority of cases, IHC showed uniform staining (3+) within a given core and in most cases cores from different patients were highly concordant. Areas of necrosis or acellular keratin were not included in the scoring. Cases were divided based on staining scores into three groups: negative/weak (0-3), moderate (4-6) or strong (7-9).

**Generation of the CSPG4-specific CAR and transduction of T lymphocytes.** The hybridoma 763.74 was generated from a BALB/c mouse immunized with cultured human melanoma cells (20). The scFv 763.74 was isolated from the hybridoma (21) and then cloned in frame with the human IgG1-CH₂CH₃ domains, the CD28 costimulatory endodomain and the CD3ζ chain into the SFG retroviral backbone (CAR.CSPG4), as previously described (22). The control CAR specific for the CD19 antigen (CAR.CD19) has been previously described (13). Transient retroviral supernatant was generated by co-transfection of 293T cells with the RD114 envelope (RDF plasmid), the MoMLV gag-pol (PegPam3-e plasmid) and the retroviral vector, as previously described (23). For the generation of CAR-T cells, peripheral blood mononuclear
cells (PBMCs) were isolated fromuffy coat preparations (Gulf Coast Regional Blood Center, Houston, TX) using Ficoll-Paque (Amersham Biosciences, Piscataway, N.J.). PBMCs were activated with OKT3 and CD28 (BD Biosciences PharMingen, San Diego, CA) mAbs, transduced with the retroviral supernatant by day 3 of culture and then expanded in complete medium containing 45% RPMI 1640 and 45% Click's medium (Irvine Scientific, Santa Ana, CA, USA) supplemented with 10% FCS, 100 IU/mL penicillin, 100 mg/mL streptomycin, and 2 mmol/L GlutaMAX. Cells were fed with IL-2 (50 U/mL) (PeproTech; Rocky Hill, NJ) twice a week for 2 weeks (23).

**Flow cytometry.** Conjugated CD3, CD4, CD8, CD45RO, CD62L and CCR7 mAbs (BD Biosciences) were used to identify T lymphocytes, while the CSPG4 mAb (Miltenyi-Biotech Inc, Auburn, CA) was used to label tumor cells. CAR expression in T lymphocytes was assessed using an antibody recognizing the human IgG1-CH2CH3 fragment (Jackson ImmunoResearch, West Grove, PN) (24). Analyses were performed on a FACsCaliber flow cytometer using the BDFACs CellQuestPro software (BD Biosciences, San Jose, CA).

**Cytotoxicity and Co-culture Assays.** The cytotoxic activity of control and CAR.CSPG4* T lymphocytes was determined using a standard 51Cr release assay at different effector-to-target (E:T) (40:1, 20:1, 10:1 and 5:1) ratios using a gamma counter (Perkin-Elmer, Waltham, MA)(25). For the co-culture experiments, control and CAR.CSPG4* T lymphocytes were plated at 1 x 10^6 cells/well in 24-well plates at different E:T ratios according to the kinetic growth of each tumor cell line. Tumor cell lines with a slow kinetic growth were plated at higher tumor ratio (T cells: tumor cells 3:1) compared to tumor cell lines with a fast kinetic growth (T cells: tumor cells 5:1). Supernatant was collected at 24 hours of culture to measure IFNγ and IL-2 release using specific ELISAs (R&D system, Minneapolis, MN). Following 72 hours of culture at 37º C, adherent tumor cells and T cells were collected and residual tumor cells and T cells assessed by FACs analysis based on GFP and CD3 expression, respectively.
**Carboxyfluorescein Diacetate Succinimidyl Ester (CFSE) Assay.** One week post transduction, control and CAR.CSPG4+ T lymphocytes were labeled with 1.5 µmol/L CFSE (Invitrogen) and plated with irradiated tumor target (SENMA) at an E:T ratio of 5:1. CFSE dilution was measured on CD4+ and CD8+ cells by flow cytometry by day 4 of co-culture.

**Xenogenic mouse models.** *In vivo* experiments were performed in accordance with Baylor College of Medicine’s Animal Husbandry guidelines. Antitumor activity of control and CAR.CSPG4+ T lymphocytes was evaluated using NOG/SCID/γc−/− mice (Jackson Lab, Bar Harbor, ME) engrafted with tumor cells. Eight to 9 week old mice were subcutaneously injected with 0.5 x 10⁶ SENMA, 3 x 10⁶ UACC-812 or 3 x 10⁶ PCI-30 cells resuspended in Matrigel (BD Biosciences, San Jose, CA). On days 4, 6, and 8 following tumor cell injection, 1 x 10⁷ control or CAR.CSPG4+ T lymphocytes were injected i.v. by tail vain. In summary, for the melanoma xenograft model 3 different preparations of CAR.CSPG4 T cells were generated from 3 different donors. Three doses, given two days apart, of 1 x 10⁷ were infused i.v. into 5 mice per group. In total, 15 animals were treated for each group. The endpoint of the experiment was to examine differences in tumor volume up to day 30-post tumor injection. For the xenograft models of breast cancer and HNSCC 2 different preparations of T cells generated from 2 different donors were used. Two doses, given two days apart, of 1 x 10⁷ were infused i.v. into 5 mice per group. In total, 10 animals were treated per group. In all tumor models, mice were sacrificed at 30 days or in accordance with our institution’s guidelines for the handling of sick animals. Weekly manual caliper measurements were performed post-treatment to evaluate tumor growth. Tumor volume was calculated using the modified ellipsoidal formula: tumor volume (mm³) = (width)² × length/2.

**Statistical Analysis.** *In vitro* data are presented as mean ± standard deviation (SD) and a paired student’s t-test was used to determine statistical significance. The *in vivo* data are presented as mean ± standard error of the mean (SEM) and a paired student’s t-test was used.
**Results**

**CSPG4 is expressed on a variety of solid tumors.** As CSPG4 was originally identified as a melanoma associated antigen, we first independently validated its expression using IHC in a melanoma tissue array containing multiple primary cutaneous and visceral melanomas and metastatic lesions. Examples of either strong or negative/low staining are shown in Fig. 1A. Consistent expression of the antigen was documented in all types of lesions, regardless of their primary or metastatic origin, or their cutaneous and visceral source. We therefore analyzed melanomas as a whole group. Overall, 59% of melanomas showed strong staining and 25% displayed moderate staining (Fig. 1B). We then extended the analysis to include multiple samples of additional solid tumors including breast cancer, HNSCC, neuroblastoma, and mesothelioma. For the breast cancer array, staining was seen in invasive ductal and lobular carcinomas as well as in the small number of Paget’s disease and ductal in situ carcinoma cases present on the array. Staining for representative invasive ductal carcinomas (either strong or negative/low) are shown in Fig. 1A and summarized in Fig. 1B, while other lesions were not sufficient in number for a comparative analysis. Staining for CSPG4 in invasive ductal carcinoma was remarkable with 77% of cases showing moderate or strong staining. HNSCC most predominantly (50%) expressed moderate staining for CSPG4, with only 20% showing strong staining. Although neuroblastoma exhibited the weakest overall staining, there was still a fraction of cases with moderate to strong expression. Finally, despite the limited number of mesotheliomas, these lesions all consistently expressed CSPG4. We concluded that, at the protein level, all these malignancies exhibited variable but in most cases significant expression of CSPG4. To examine the expression of CSPG4 in a broader array of tumors we examined publicly available databases for mRNA expression data. As shown in Fig. 1C, examination of TCGA datasets showed over expression of CSPG4 transcripts in melanoma and in glioma as anticipated based on the previously reported expression of the protein (28). Concordant with our
protein expression data, CSPG4 mRNA expression was increased in HNSCC. We also found increased mRNA expression in clear cell renal carcinomas by in silico analysis, and overall, despite some intratumor variability, significant increased mRNA levels in all these tumor types relative to the corresponding normal tissues (Fig. 1D). Examination of the large Bittner multicancer dataset (www.oncomine.org) confirmed high CSPG4 mRNA expression in melanoma, clear cell renal carcinoma, HNSCC, multiple sarcoma types (chondrosarcoma, leiomyosarcoma, liposarcoma), gastrointestinal stromal tumors, skin, and vulvar squamous cell carcinomas (Supplementary Fig. 1). Of note several sarcoma cell lines have been previously reported to express CSPG4 protein (29). A number of other common malignancies such as colorectal, ovarian, and endometrial carcinoma did not show increased CSPG4 transcripts, consistent with the mRNA expression from the TCGA data sets. CSPG4 protein expression in an array of normal tissues was negative (Supplementary Fig. 2). In addition to the normal tissues represented in supplementary figure 2, we evaluated CSPG4 expression on a total of 33 different types of tissues, all of which were negative. Using the public Novartis GeneAtlas (http://biogps.org) and TCGA databases, CSPG4 mRNA expression was observed in a number of normal tissues. However, the levels of expression are remarkably lower than those of cancer tissues (Supplementary Fig. 3).

We next examined CSPG4 expression in a series of cell lines from a variety of tumor types analyzed above. Expression of CSPG4 was detected in 8 of the 9 melanoma cell lines screened (Fig. 1E). Importantly, CSPG4 was detected on tumor cell lines representative of the above identified solid tumors such as mesothelioma (MILL and PHI), HNSCC (PCI-30) and breast cancer [MDA-MB-231 (adenocarcinoma) and UACC-812 (ductal carcinoma)] (Fig. 1F) all consistent with our analysis of human tumor samples.

T lymphocytes expressing the CSPG4-specific CAR are cytotoxic against CSPG4+ tumor cell lines but not against primary normal tissues. To target CSPG4+ tumors we generated a
CSPG4-specific CAR containing the CD28 costimulatory endodomain (CAR.CSPG4) (Fig. 2A). T lymphocytes from 4 healthy donors were engineered to express the CAR.CSPG4 using a gamma retroviral vector. Transduction efficiency was 80% ± 3%, and both CD4 and CD8 T cells stably expressed the CAR (26% ± 9% and 51% ± 16%, respectively), as assessed by phenotypic analysis by day 7 of culture (Fig. 2B). The majority of CAR.CSPG4+ T cells were CD45RO+ (76% ± 7%) and a fraction retained CD62L expression (51% ± 7%) and CCR7 (13% ± 2%), indicating that they were mainly composed of effector-memory T cells (Fig. 2C). The expression of CAR.CSPG4 by T cells was comparable to that obtained with a previously described CD19-specific CAR (CAR.CD19) (Supplementary Fig. 4) (30), which was used as an irrelevant-CAR control population.

Cytotoxic activity of control and CAR.CSPG4+ T cells, after 1-2 weeks of culture, was assessed against K562, to measure natural killer cell-mediated activity, and against the melanoma derived cells lines P1143 (as CSPG4- target) and SENMA (as CSPG4+ target) (Fig. 1E) at various E:T ratios (Fig. 3A). CAR.CSPG4+ but not control T lymphocytes significantly lysed the CSPG4+ target (59% ± 5% vs. 11% ± 8% at 20:1 ratio)(p< 0.01), while both CAR.CSPG4+ and control T cells showed minimal activity against K562 (12% ± 9% vs. 13% ± 11%) and the CSPG4- target (<10% in both cases). The antitumor activity of CAR.CSPG4+ T lymphocytes was also evaluated in a 72 hour co-culture assay (Fig. 3B and C). CAR.CSPG4+ and control T lymphocytes were co-cultured with GFP-expressing tumor cell lines at an E:T ratio ranging from 5:1 to 3:1 according to the kinetic growth of each cell line. CAR.CSPG4+ T cells significantly controlled the growth of all CSPG4+ cell lines tested: SENMA (residual tumor cells = 0.1% ± 0.06%), CLB (0.1% ± 0.1%), UACC-812 (6% ± 6%), MILL (3% ± 5%), MDA-MB-231 (3% ± 3%), PHI (4% ± 3%), and PCI-30 (0.5% ± 0.5%), but not of the CSPG4- target P1143 (residual tumor cells 38% ± 10%). As expected, all tumor cell lines tested rapidly grow in the presence of control T lymphocytes (residual tumor cells for: SENMA = 62% ± 3%, CLB = 70% ± 6%, UACC-812 =
47% ± 15%, MILL = 50% ± 8%, MDA-MB-231 = 42% ± 11%, PHI = 29% ± 6%, PCI-30 = 17% ±
3%, and P1143 = 45% ± 10%). In all cases, the effects of CAR.CSPG4+ T cells were
significantly greater than those of control T cells (from p<0.05 to p<0.001). T cells expressing
the control CAR.CD19 showed cytotoxic activity neither against CSPG4+ nor CSPG4- targets
(Supplementary Fig. 4). As illustrated in Fig. 3, commercially available primary normal
epithelial cell lines (small airway, kidney and prostate) derived from tissues found to express
low levels of CSPG4 mRNA (Supplementary Fig. 3) did not express detectable levels of the
protein by flow cytometry (Fig. 3D), and were not lysed by CAR.CSPG4+ T cells when tested in
51Cr release assays (Fig. 3E).

CAR.CSPG4+ T lymphocytes secrete Th1 cytokines and proliferate in response to
CSPG4+ tumors. Since CAR.CSPG4 contains the CD28 costimulatory endodomain, we studied
CAR.CSPG4+ T lymphocyte proliferation in response to CSPG4+ tumor cells using a CFSE
dilution assay. When CFSE-labeled control and CAR.CSPG4+ T cells were cultured with
irradiated SENMA tumor cells for 96 hours, a significant CFSE dilution occurred for
CAR.CSPG4+ T cells, with both CD4 and CD8 T cells proliferating at a higher percentage (66%
± 12% and 68% ± 8%, respectively) compared to control CD4 and CD8 T cells (8% ± 7% and
14% ± 10%, respectively) (p<0.05 and p<0.01, respectively) (Fig. 4A and B). T cells transduced
with the control CAR.CD19 also containing the CD28 endodomain did not show significant
proliferation in response to CSPG4+ targets (Supplementary Fig. 4). We also evaluated
whether the inclusion of a “late” co-stimulatory endodomain, such as 4-1BB, in addition to CD28
(third generation construct) provided these T cells with additional proliferative and cytotoxic
activity, but found no further benefits (Supplementary Fig. 5).

We finally quantified the IL-2 and IFNγ cytokines released in response to the antigen, by co-
culturing control and CAR.CSPG4+ T lymphocytes with CSPG4+ or CSPG4- tumor cells. As
expected CAR.CSPG4+ T lymphocytes secreted significantly more IL-2 than control T cells only
in the presence of CSPG4⁺ tumor cells (Fig. 4C). A positive trend, although not statistically significant, was observed when CAR.CSPG4⁺ T lymphocytes were cultured with the MSCP⁺ tumor cell lines PHI, MILL, UACC-812 and MDA-MB-231 (data not shown). Similarly IFNγ production was significantly higher than control T cells when CAR.CSPG4⁺ T lymphocytes were cultured with CSPG4⁺ tumor cells (Fig. 4D).

**CAR.CSPG4⁺ T lymphocytes control the growth of human melanoma, HNSCC and breast carcinoma cells engrafted in immunodeficient mice.** To assess the *in vivo* relevance of our *in vitro* results, we engrafted NSG mice subcutaneously with cell lines derived from representative melanoma tumor (SENMA), HNSCC (PCI-30) or breast carcinoma (UACC-812). Four to seven days later (depending on the kinetics of the tumor growth), mice were infused via tail vein injection with either control or CAR.CSPG4⁺ T lymphocytes, and tumor growth quantified by sequential tumor volume measurements. In all three models, CAR.CSPG4⁺ T lymphocytes inhibited tumor growth significantly better than control T lymphocytes (Fig. 5). By day 30, melanoma tumors reached a volume of 879 mm³ ± 124 mm³ in mice receiving CAR.CSPG4⁺ T lymphocytes versus 8359 mm³ ± 958 mm³ in mice receiving control T cells (p<0.001) (Fig. 5A), and this corresponded to improved overall survival (Supplementary Fig. 6). Although HNSCC and breast carcinoma tumors were not as aggressive as melanoma *in vivo*, we observed that in both models CAR.CSPG4⁺ T lymphocytes controlled tumor growth. By day 30 the size of HNSCC tumors was 19 mm³ ± 10 mm³ in treated mice versus 190 mm³ ± 75 mm³ in control mice (p<0.001) (Fig. 5B) and the size of breast carcinoma tumors was 28 mm³ ± 13 mm³ in treated mice versus 166 mm³ ± 64 mm³ in control mice (p< 0.001) (Fig. 5C).
Discussion

The involvement in several signaling pathways associated with cell proliferation, survival, migration, and suggested high expression in various types of cancers highlight the critical role that CSPG4 has in promoting tumor growth and simultaneously make it an attractive target for immunotherapy. By IHC, we independently validated CSPG4 protein expression in several solid tumors with poor prognosis, such as melanoma, breast cancer, mesothelioma and HNSCC. In silico analysis of microarray expression data confirmed overexpression of CSPG4 in tumors that we validated by IHC as compared to normal tissues, and also disclosed CSPG4 overexpression in other important malignancies including glioblastoma, clear cell renal carcinoma and sarcomas suggesting that targeting this antigen may have a major impact on a broad array of solid tumors.

Since CSPG4-specific mAbs can control tumor growth of CSPG4⁺ tumor cells, in both melanoma and breast cancer tumor models (7, 31), we proposed to improve the therapeutic benefits of this antibody-based approach by generating a CAR that targets the CSPG4 molecule. In contrast to mAb-based therapy, CAR-T cells should produce long-lasting effects, as engineered T cells can expand at the tumor site upon antigen stimulation if an appropriate costimulatory endodomain, derived from CD28, CD137 or CD134, is incorporated within the CAR (13, 31). In contrast to a previous report (21), we found that the CSPG4-specific CAR obtained from the same 763.74 single chain has potent antitumor activity. We traced these striking differences to two critical components we have introduced in our construct. First, the scFv in our CAR is coupled with the CD3-ζ endodomain of the TCR rather than the FcεRI-γ chain, which is known to promote a much weaker and less durable signaling (32, 33). Second, we incorporated the CD28 costimulatory endodomain within the CAR, to accomplish sustained IL-2 production and proliferation in response to CSPG4⁺ tumor cells, thus recapitulating
previous observations for other CAR molecules (13). Of note, the inclusion of a second costimulatory endodomain derived from CD137 did not further improve the function of our CAR in vitro, supporting the concept that there is no single optimal configuration that is applicable to all CAR molecules, but that CAR receptor optimization remains largely empirical and required for each molecule.

The most critical improvement in the field by our work is the applicability of CAR.CSPG4* T cells not only to target melanoma (17), but more broadly to other solid tumors generally characterized by poor prognosis with conventional treatments such as breast carcinoma, HNSCC and mesothelioma. We demonstrated that CAR.CSPG4* T cells produce IFNγ and promote tumor elimination not only when challenged with tumor cells with high CSPG4 expression but also with tumor cell lines characterized by moderate/low CSPG4 expression, such as the breast carcinoma tumor cell lines UACC-812 and MBA-MB-231. This further supports the advantages of antibody specificity coupled with the T-cell effector function, as mastered by CAR-modified T cells, which can target tumors neglected by naked corresponding antibodies due to the suboptimal expression of the targeted antigen (34, 35).

Antitumor effects mediated by CAR.CSPG4* T cells significantly limit tumor growth in xenograft mouse models of melanoma, HNSCC and breast carcinoma, strongly validating our in vitro findings. The lack of sustained and complete tumor eradication in these models was not caused by selection of CSPG4-negative tumor cells, as harvested tumors retained the expression of the antigen (Supplementary Fig. 6), but conversely are likely to be attributed to an intrinsic limitation of the models, as T cells do not persist long term in these immunodeficient mice (Supplementary Fig. 6).

To fully translate this approach, the differential expression of CSPG4 in tumor cells versus normal tissues needs to be ensured in order to limit potential toxicities (36, 37). We found the
expression of CSPG4 absent or negligible in normal tissue arrays as assessed by IHC. The analysis of publically available data sets indicates that there is some level of CSPG4 mRNA expression in several normal tissues. However, when we compared normal tissues with cancer tissues, the cancers show consistent and dramatically higher expression of CSPG4 at mRNA levels, and our in vitro analyses illustrate that primary epithelial cells derived from some of these tissues do not express significant amount of the protein and are not targeted by CAR.CSPG4^+ T cells. Even though the tissue screening, bioinformatics analysis and lack of toxicity by in vitro experiments support the relevance of CSGP4 as a targetable antigen in cancer patients, we cannot fully exclude that the low levels of mRNA in normal tissues, as reported in public data sets, may promote sufficient protein expression in specific physiological conditions to become a target for CSPG4-specific CAR-T cells. The clinical translation of this approach may thus benefit from the inclusion of a suicide gene within the vector cassette, to allow the rapid elimination of CAR-modified T cells in case of undesired toxicity (30, 38).

In summary, we provide ample data to support the use of CAR.CSPG4^+ T cells to treat a broad range of solid CSPG4^+ tumors for which the prognosis remains poor with conventional treatments. The combination of this approach with other biological agents may further increase their activity and thus clinical benefits.
Figure legends

Figure 1. CSPG4 expression in primary solid tumors and tumor-derived cell lines. Panel A. Representative immunohistochemistry (IHC) and scoring of analyzed solid tumor tissue arrays. Representative melanoma and breast carcinoma samples are shown at 200X magnification. Panel B. Scoring summary of a panel of solid tumors which includes melanoma, breast carcinoma (Breast CA), HNSCC, neuroblastoma (NeuroB) and mesothelioma (MesoT). Panel C. CSPG4 mRNA expression by TCGA in a variety of solid tumors. Box plots show median, 25%/75% range, 5%/95% range, and minimum/maximum. Panel D. CSPG4 mRNA expression analysis, comparing tumor versus corresponding normal tissues, for astrocytoma/glioblastoma (GBM), HNSCC, clear cell renal carcinoma, and melanoma. Indicated P-values were calculated by t-test. Panel E. CSPG4 expression in the indicated array of melanoma cell lines as assessed by flow cytometry (FACS). Panel F. FACS analysis of CSPG4 expression in the selected mesothelioma (MILL and PHI), HNSCC (PCI-30), and breast cancer-derived (MDA-MB-231 and UACC-812) cells lines. Dotted and bold lines indicate isotype and CSPG4 mAbs, respectively.

Figure 2. Expression and function of CAR.CSPG4 in T cells. Panel A. Schematic representation of the retroviral vector encoding the CSPG4-specific CAR. The CAR incorporates the CD28 costimulatory endodomain. Panel B. Representative FACS analysis showing the expression of the CAR in CD3, CD4 and CD8 T cells after retroviral transduction. Panel C. Representative expression of the CD62L, CD45RO, and CCR7 markers on control and CAR.CSPG4+ T cells by flow cytometry on day 14 of culture. Numbers represent percentages of cells per quadrant.

Figure 3. Cytotoxic function of CAR.CSPG4+ T cells against CSPG4+ tumors but not against epithelial cells from lung, kidney and prostate. Panel A. Cytotoxic activity of control
T cells and CAR.CSPG4+ T cells evaluated in a 6 hour $^{51}$Cr release assay. Target cells used were the CSPG4+ tumor cell line (SENMA), CSPG4− target cell line (P1143) and K562 to quantify natural killer activity. Data show averages and SD results of T cells from 4 donors. **Panel B.** Co-culture experiments of control and CAR.CSPG4+ T cells with GFP+ tumor cell lines, assessed by flow cytometry 72 hours later. The plots describe a representative experiment of T cells co-cultured with SENMA (CSPG4+ target) or P1143 (CSPG4− target). Numbers represent percentages of cells per quadrant. **Panel C.** Summary of co-culture experiments of control and CAR.CSPG4+ T cells against a panel of CSPG4+ tumor targets. Data represent averages ± SD of 4 donors. * = p<0.05, and *** = p<0.001. **Panel D.** FACS analysis of CSPG4 expression in primary epithelial cells derived from normal small airway, kidney and prostate. Dotted and bold lines indicate isotype and CSPG4 mAbs, respectively **Panel E.** Cytotoxic activity of control T cells and CAR.CSPG4+ T cells from a representative donor of two independent experiments evaluated in a 5 hour $^{51}$Cr release assay against these normal epithelial cells.

**Figure 4.** T lymphocytes transduced with CAR.CSPG4 proliferate and release IL-2 and IFNγ upon specific antigen engagement. **Panel A.** Control and CAR.CSPG4+ T cells, labeled with CFSE, were stimulated with irradiated CSPG4+ (SENMA) tumor target. The panel illustrates the CFSE dilution in CD4 or CD8 gated T cells after 96 hours of culture for a representative donor. **Panel B.** Summary of 3 independent CFSE dilution assays. Data represents mean ± SD. **Panel C.** IL-2 cytokine-release assessment using specific ELISA by T lymphocytes transduced with CAR.CSPG4 and control T cells 24 hours post co-culture (E:T ratio 5:1) with either CSPG4+ tumors or CSPG4− target cells (P1143). Results of 5 experiments are presented with mean ± SD. **Panel D** illustrates the detection of IFNγ in the same culture supernatant. Results of 5 experiments with mean ± SD are shown. * = P< 0.05, ** = p<0.01, and *** = p<0.001.
Figure 5. CAR.CSPG4+ T lymphocytes control tumor growth in vivo. Panels show tumor growth, assessed by caliper measurement, of NSG mice engrafted subcutaneously with melanoma (SENMA) (Panel A), HNSCC (PCI-30), (Panel B) or breast carcinoma (UACC-812) (Panel C) cell lines and infused i.v. with either CAR.CSPG4+ (closed squares) or control (closed circles) T lymphocytes. Arrows indicate T-cell infusions. Shown are mean ± SD from 15 mice per group (3 independent experiments) for the melanoma model and 10 mice per group (2 independent experiments) for the HNSCC model and breast carcinoma models. *** = p< 0.001.
Reference List


Fig 2

A

5LTR ScFv 783.74 Spacer CD28 ζ 3LTR

B

Control

CAR.CSP04

C

Control

CAR.CSP04
**Clinical Cancer Research**

**T lymphocytes redirected against the chondroitin sulfate proteoglycan-4 control the growth of multiple solid tumors both in vitro and in vivo**

Claudia Geldres, Barbara Savoldo, Valentina Hoyos, et al.

*Clin Cancer Res* Published OnlineFirst December 13, 2013.

<table>
<thead>
<tr>
<th>Updated version</th>
<th>Access the most recent version of this article at: doi:10.1158/1078-0432.CCR-13-2218</th>
</tr>
</thead>
<tbody>
<tr>
<td>Supplementary Material</td>
<td>Access the most recent supplemental material at: <a href="http://clincancerres.aacrjournals.org/content/suppl/2013/12/13/1078-0432.CCR-13-2218.DC1">http://clincancerres.aacrjournals.org/content/suppl/2013/12/13/1078-0432.CCR-13-2218.DC1</a></td>
</tr>
<tr>
<td>Author Manuscript</td>
<td>Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.</td>
</tr>
</tbody>
</table>

---

**E-mail alerts** | Sign up to receive free email-alerts related to this article or journal. |
**Reprints and Subscriptions** | To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org. |
**Permissions** | To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org. |